Exocrine Pancreatic Insufficiency Epidemiology Forecast

DelveInsight's 'Exocrine Pancreatic Insufficiency - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Exocrine Pancreatic Insufficiency epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Exocrine Pancreatic Insufficiency Understanding

The DelveInsight Exocrine Pancreatic Insufficiency epidemiology report gives a thorough understanding of the Exocrine Pancreatic Insufficiency by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Exocrine Pancreatic Insufficiency in the US, Europe, and Japan. The report covers the detailed information of the Exocrine Pancreatic Insufficiency epidemiology scenario in seven major countries (US, EU5, and Japan).


Exocrine Pancreatic Insufficiency Epidemiology Perspective by DelveInsight

The Exocrine Pancreatic Insufficiency epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Exocrine Pancreatic Insufficiency epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Exocrine Pancreatic Insufficiency epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Exocrine Pancreatic Insufficiency Detailed Epidemiology Segmentation

The Exocrine Pancreatic Insufficiency epidemiology covered in the report provides historical as well as forecasted Exocrine Pancreatic Insufficiency epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Exocrine Pancreatic Insufficiency report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Exocrine Pancreatic Insufficiency report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Exocrine Pancreatic Insufficiency Epidemiology Report and Model provide an overview of the risk factors and global trends of Exocrine Pancreatic Insufficiency in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Exocrine Pancreatic Insufficiency in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Exocrine Pancreatic Insufficiency
  • The report provides the segmentation of the Exocrine Pancreatic Insufficiency epidemiology


Report Highlights

  • 11-Year Forecast of Exocrine Pancreatic Insufficiency epidemiology
  • 7MM Coverage
  • Total Cases of Exocrine Pancreatic Insufficiency
  • Total Cases of Exocrine Pancreatic Insufficiency according to segmentation
  • Diagnosed cases of Exocrine Pancreatic Insufficiency


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Exocrine Pancreatic Insufficiency?
  • What are the key findings pertaining to the Exocrine Pancreatic Insufficiency epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Exocrine Pancreatic Insufficiency across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Exocrine Pancreatic Insufficiency?
  • What are the currently available treatments of Exocrine Pancreatic Insufficiency?


Reasons to buy

  • The Exocrine Pancreatic Insufficiency Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Exocrine Pancreatic Insufficiency market
  • Quantify patient populations in the global Exocrine Pancreatic Insufficiency market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Exocrine Pancreatic Insufficiency therapeutics in each of the markets covered
  • Understand the magnitude of Exocrine Pancreatic Insufficiency population by its epidemiology
  • The Exocrine Pancreatic Insufficiency Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1 Key Insights

2 Executive Summary

3 SWOT Analysis

4 Exocrine Pancreatic Insufficiency (EPI) Overview at a Glance

4.1 Patient Share (%) Distribution of Exocrine Pancreatic Insufficiency (EPI) in 2017

4.2 Patient Share (%) Distribution of Exocrine Pancreatic Insufficiency (EPI) in 2030

5 Disease Background and Overview: Exocrine Pancreatic Insufficiency (EPI)

5.1 Introduction

5.2 Biology and pathology of Exocrine Pancreatic Insufficiency

5.3 Pathophysiology of EPI

5.4 Causes and Risk Factors of EPI

5.4.1 EPI caused by pancreatic disorders

5.4.2 EPI caused by extrapancreatic disorders

5.5 Serum nutritional markers for prediction of pancreatic exocrine insufficiency in chronic pancreatitis

5.5.1 Disorders of Carbohydrate Metabolism

5.5.1 Disorders of Lipid Metabolism

5.6 Diagnosis

5.6.1 Fecal elastase-1 test (FE-1)

5.6.2 Serum trypsinogen

5.6.3 Fecal chymotrypsin

5.6.4 Breath tests

5.6.5 Coefficient of fat absorption (CFA)

5.6.6 Preoperative Evaluation

5.6.7 Direct pancreatic function test

5.6.8 Secretin-enhanced magnetic resonance cholangiopancreatography (MRCP)

5.6.9 Differential Diagnosis of exocrine pancreatic insufficiency

6 Recognized Establishments

7 Epidemiology and Patient Population

7.1 Key Findings

7.2 7 Major Markets

7.2.1 Prevalence of Causative Indications of EPI in the 7MM

7.2.2 Prevalence of Exocrine Pancreatic Insufficiency in the 7MM

8 Country-wise Epidemiology of Exocrine Pancreatic Insufficiency (EPI)

8.1 Assumption and Rationale

8.1 United States

8.1.1 Prevalence of Causative Indications of EPI in the United States

8.1.2 Prevalence of Exocrine Pancreatic Insufficiency in the United States

8.2 EU5 Countries

8.2.1 Assumption and Rationale

8.3 Germany

8.3.1 Prevalence of Causative Indications of EPI in Germany

8.3.2 Prevalence of Exocrine Pancreatic Insufficiency in Germany

8.4 France

8.4.1 Prevalence of Causative Indications of EPI in France

8.4.2 Prevalence of Exocrine Pancreatic Insufficiency in France

8.5 Italy

8.5.1 Prevalence of Causative Indications of EPI in Italy

8.5.2 Prevalence of Exocrine Pancreatic Insufficiency in Italy

8.6 Spain

8.6.1 Prevalence of Causative Indications of EPI in Spain

8.6.2 Prevalence of Exocrine Pancreatic Insufficiency in Spain

8.7 The United Kingdom

8.7.1 Prevalence of Causative Indications of EPI in the United Kingdom

8.7.2 Prevalence of Exocrine Pancreatic Insufficiency in the United Kingdom

8.8 Japan

8.8.1 Assumption and Rationale

8.8.2 Prevalence of Causative Indications of EPI in Japan

8.8.3 Prevalence of Exocrine Pancreatic Insufficiency in Japan

9 Appendix

10 DelveInsight Capabilities

11 Disclaimer

12 About DelveInsight

Table 1: Summary of Exocrine Pancreatic Insufficiency (EPI) Epidemiology, and Key Events (2017–2030)

Table 2: Summary of Exocrine Pancreatic Insufficiency (EPI) in the 7MM, and Key Events (2017–2030)

Table 3: Common symptoms shared by EPI and other gastrointestinal conditions

Table 4: EPI caused by pancreatic disorders

Table 5: EPI caused by extrapancreatic disorders

Table 6: Pancreatic Function Tests—Indirect and Direct Tests

Table 7: Prevalence of Causative Indications of EPI in the 7MM (2017–2030)

Table 8: Prevalence of Exocrine Pancreatic Insufficiency in the 7MM (2017–2030)

Table 9: Prevalence of exocrine pancreatic insufficiency in individuals with predisposing conditions

Table 10: Prevalence of Causative Indications of EPI in the United States (2017–2030)

Table 11: Prevalence of Exocrine Pancreatic Insufficiency in the United States (2017–2030)

Table 12: EPI caused by pancreatic disorders

Table 13: Prevalence of Causative Indications of EPI in Germany (2017–2030)

Table 14: Prevalence of Exocrine Pancreatic Insufficiency in Germany (2017–2030)

Table 15: Prevalence of Causative Indications of EPI in France (2017–2030)

Table 16: Prevalence of Exocrine Pancreatic Insufficiency in France (2017–2030)

Table 17: Prevalence of Causative Indications of EPI in Italy (2017–2030)

Table 18: Prevalence of Exocrine Pancreatic Insufficiency in Italy (2017–2030)

Table 19: Prevalence of Causative Indications of EPI in Spain (2017–2030)

Table 20: Prevalence of Exocrine Pancreatic Insufficiency in Spain (2017–2030)

Table 21: Prevalence of Causative Indications of EPI in the United Kingdom (2017–2030)

Table 22: Prevalence of Exocrine Pancreatic Insufficiency in the United Kingdom (2017–2030)

Table 23: Prevalence of Causative Indications of EPI in Japan (2017–2030)

Table 24: Prevalence of Exocrine Pancreatic Insufficiency in Japan (2017–2030)

Figure 1: Exocrine Pancreatic Insufficiency SWOT Analysis

Figure 2: The pathology of exocrine pancreatic insufficiency

Figure 3: Relationship between extrapancreatic diseases/conditions and PEI.

Figure 4: Basis of pancreatic function breath tests.

Figure 5: Prevalence of Causative Indications of EPI in the 7MM (2017–2030)

Figure 6: Prevalence of Exocrine Pancreatic Insufficiency in the 7MM (2017–2030)

Figure 7: Prevalence of Causative Indications of EPI in the United States (2017–2030)

Figure 8: Prevalence of Exocrine Pancreatic Insufficiency in the United States (2017–2030)

Figure 9: Prevalence of Causative Indications of EPI in Germany (2017–2030)

Figure 10: Prevalence of Exocrine Pancreatic Insufficiency in Germany (2017–2030)

Figure 11: Prevalence of Causative Indications of EPI in France (2017–2030)

Figure 12: Prevalence of Exocrine Pancreatic Insufficiency in France (2017–2030)

Figure 13: Prevalence of Causative Indications of EPI in Italy (2017–2030)

Figure 14: Prevalence of Exocrine Pancreatic Insufficiency in Italy (2017–2030)

Figure 15: Prevalence of Causative Indications of EPI in Spain (2017–2030)

Figure 16: Prevalence of Exocrine Pancreatic Insufficiency in Spain (2017–2030)

Figure 17: Prevalence of Causative Indications of EPI in the United Kingdom (2017–2030)

Figure 18: Prevalence of Exocrine Pancreatic Insufficiency in the United Kingdom (2017–2030)

Figure 19: Prevalence of Causative Indications of EPI in Japan (2017–2030)

Figure 20: Prevalence of Exocrine Pancreatic Insufficiency in Japan (2017–2030)

  • Tags:
  • Exocrine Pancreatic Insufficiency E...
  • Exocrine Pancreatic Insufficiency
  • Exocrine Pancreatic Insufficiency...
  • Exocrine Pancreatic Insufficiency...
  • Exocrine Pancreatic Insufficiency...
  • Exocrine Pancreatic Insufficiency...
  • Exocrine Pancreatic Insufficiency...
  • Exocrine Pancreatic Insufficiency...

Forward to Friend

Need A Quote